

Situation report

dieKontrollgruppe

October 31, 2022


1 Introduction

dieKontrollgruppe is an anonymous and independent scientific monitoring of Corona-vaccinated and Corona-unvaccinated people. Our aim is to use the information obtained in the coming months and years to obtain early indications of both the positive effects and any undesirable side effects of the vaccinations against the SARS-CoV-2 virus.


To ensure high data quality and serious cooperation, registration for monitoring is only possible via multipliers. Multipliers have been personally verified by the core team of **dieKontrollgruppe**. Registration includes access to the control group web interface, where the intake questionnaire and the individual fortnightly surveys can be completed.

dieKontrollgruppe was launched on 10.8.2021. Preliminary results are shown here.


2 Participants in monitoring




The total number of participants in a given calendar week is shown. Participants who have completed the intake form are counted. So far, the proportion of unvaccinated participants exceeds that of vaccinated participants.




Cumulative number of vaccinated in monitoring who completed surveys, divided into participants vaccinated at intake and originally unvaccinated.



Most participants are between 50 and 60 years old. In comparison the age pyramid in Germany, younger people are underrepresented. The average age of the vaccinated is slightly above that of the control group.




The body mass index (BMI) is typical for a cohort in Germany (average BMI 25.7). The BMI of the vaccinated is slightly higher than that of the control group.



The majority of participants are female. The proportion in the control group is even slightly higher.

How do you treat yourself in the event of an illness?




The high number of participants who rely on their own expertise is not surprising, as people who are willing to participate in a health monitoring programme attach a high value to the topic of health.


The high number of those who rely on homeopathy is certainly due to the fact that the control group was presented for the first time at a homeopathy conference.

Also not surprising is the higher rate of vaccinated patients among those who primarily treated with conventional medicine.

Participants by country




Most of the participants come from Germany, but increasingly also from Austria and Switzerland.




Shown here is the total number of completed fortnightly surveys.

3 Occurrence of symptoms



The occurrence of a new symptom is shown according to calendar week and vaccination status, i.e. if the question "Have you had a NEW symptom in the last 14 days?" was answered with "Yes". In the error bar in this diagram—as well as in the following ones—the 95% confidence interval is shown according to the exact Clopper-Pearson method.


New diagnoses



The occurrence of a new medical diagnosis is shown according to calendar week and vaccination status, i.e. if the question "Have you had a NEW diagnosis or disease in the last 14 days?" was answered with "Yes".


3.1 New symptoms

The answer to the question Have you had a NEW complaint in the last 14 days? The answer is broken down by Covid vaccination status. For persons who were vaccinated during the course of the interviews, interviews prior to vaccination are assigned to the control group and interviews after vaccination are assigned to the vaccinated group.



14.3% ($n = 16750$) of the non-vaccinated reported a new complaint in the last 14 days, among the vaccinated this was in 20.2% ($n = 1255$) the case. The vaccinated people thus suffered 1.41 times more often from symptoms than the control group. The difference in proportions has significance $p = 4.17 \cdot 10^{-34}$ (Fisher exact test) and an odds ratio of 0.662 (95% confidence interval 0.62 to 0.706). The confidence interval does not contain one and supports the significance statement.

3.2 Respiratory diseases




The occurrence of respiratory diseases is shown according to calendar week and vaccination status. Respiratory diseases are characterised by rhinitis, cough or sore throat. In people, people who entered the survey unvaccinated and were later vaccinated vaccinated, the interviews before vaccination are assigned to the unvaccinated status. unvaccinated status, and the interviews afterwards are assigned to the vaccinated status. In the error bar in this diagram as well as in the following ones, the 95% confidence interval according to the exact Clopper-Pearson Clopper-Pearson method.

Among the unvaccinated, there is an even seasonal development that peaked at the end of October and has been falling again since then. falling since then. This trend is earlier than the typical seasonal trend. earlier.


Among the vaccinated, the course is characterised by strong fluctuations (which are also partly due to the small number of cases, represented by the confidence interval). The general frequency of respiratory diseases differs little from the control group to the vaccinated, however, among the vaccinated there are maxima in October and January.

Severity-weighted frequency of respiratory diseases



Shown is a representation of the occurrence of respiratory diseases weighted by severity. occurrence of respiratory diseases. The monitoring records symptoms in 5 severity levels from very mild to very severe, which are assigned numerical values from 1 to 5. For the severity of a respiratory illness, the severity of the cold, cough and sore cough and sore throat are added together to give an overall score of 1 to 15. 15, whereby the percentage of the maximum possible 15 is shown here.


Influenza-like illnesses



The occurrence of influenza infections is shown according to calendar week and vaccination status. Influenza infections are counted if one of the symptoms fever, chills or aching limbs has occurred in addition to a respiratory illness, chills or aching limbs.


Among the unvaccinated, there is an increase up to the 42nd calendar week and then a slow decline. Among the vaccinated, on the other hand vaccinated, there is a marked increase in frequency in the 40th calendar week and in January. In the 3rd calendar week, the frequency is 3 times higher in the vaccinated than in the unvaccinated.

Severity-weighted frequency of influenza-like illnesses



A representation of the occurrence of influenza infections weighted according to severity is shown. occurrence of influenza infections. For the severity of an influenza the severity of a cold, cough, sore throat, fever, chills and aching limbs, fever, chills and aching limbs are added together to give an overall score of 1 to from 1 to 30, where again the percentage of the maximum possible possible 30 is shown.

3.3 Occurrence of specific symptoms




Symptom	Factor vaccinated vs. non-vaccinated		Cases	
	Frequency	Severity	Non-vaccinated	Vaccinated
Rhinitis	1.27***	1.09***	7277	490
Sore throat	1.31***	1.13***	6100	424
Cough	1.31***	1.04	5661	396
Limb pain	1.48***	1.03	2953	233
Chills	1.37**	0.91*	1445	105
Fever	1.29**	0.97	2177	150
Cardiovascular problems	2.46***	1.13**	1101	144
Bruises	4.15***	1.16*	240	53
Disorder of the lymph systems	2.26**	1.23*	183	22
Dyspnea	2.26***	1.09*	1079	130
Gastrointestinal problems	1.49***	1.03	2425	192
Food intolerance	1.83**	1.07	257	25
Loss of smell	0.75	0.78*	723	29
Chest pains	3.42***	1.08	538	98
Headache	1.51***	1.02	4562	367
Fatigue	1.54***	1.04*	5203	425
Lack of motivation	1.65***	1.01	3567	313
Insomnia	2.01***	1.02	2022	216
Restlessness	1.82***	0.99	1169	113
Tenseness	1.95***	0.97	1380	143
Anxiety states	1.51***	1.04	944	76
Double vision (diplopia)	2.91***	0.97	142	22
Concentration difficulties	2.27***	1.03	1266	153
Word finding disorders	2.95***	0.99	649	102
Coordination difficulties	3.58***	1.02	247	47
Neurological disorders	3.06***	0.96	209	34
Paresthesia on the skin	2.13***	1.15*	495	56
Ekzema, Dermatitis	2.53***	1.03	535	72
Allergies	2.24***	1.16*	412	49
Herpes zoster	1.47	1.09	332	26
Joint inflammation	3.14***	1.10	461	77
Overdue menses	5.88***	0.92	99	31
Increased menstrual problems	1.72*	0.85	241	22
General overall symptoms (e.g. migraine) improved	2.04*	0.94	129	14
Increased general overall symptoms	2.33***	1.01	411	51
Remarkable weight gain	2.62***	1.15	172	24

This table contains a brief summary of the individual symptoms described below. The factor is shown with which the frequency or severity of symptoms is more frequent or more severe in the or more severe in the vaccinated than in the unvaccinated. The significance is marked with *** if $p < 0.001$, with ** if $p < 0.01$ and with *, if $p < 0.05$.

3.4 New symptom: Rhinitis


The occurrence of the symptom “Rhinitis” to the question “Have you experienced a NEW symptom in the last 14 days?”.



6.23% ($n = 7277$) of the non-vaccinated reported that the new symptom Rhinitis had occurred in the last 14 days, compared to 7.88% ($n = 490$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.27 times more often than the control group. The difference in proportions has the significance $p = 4.11 \cdot 10^{-7}$ (Fisher exact test) and an odds ratio of 0.776 (95% confidence interval of 0.706 to 0.856). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.29 in the control group and 2.48 in the vaccinated. Thus, the average severity was 1.09 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.000491$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0374.

The average severity of the symptom across all interviews is 1.37 times higher in vaccinated than in the non-vaccinated.



3.5 New symptom: Sore throat


The occurrence of the symptom “Sore throat” to the question “Have you experienced a NEW symptom in the last 14 days?”.



5.22% ($n = 6100$) of the non-vaccinated reported that the new symptom Sore throat had occurred in the last 14 days, compared to 6.82% ($n = 424$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.31 times more often than the control group. The difference in proportions has the significance $p = 1.2 \cdot 10^{-7}$ (Fisher exact test) and an odds ratio of 0.753 (95% confidence interval of 0.679 to 0.835). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.24 in the control group and 2.53 in the vaccinated. Thus, the average severity was 1.13 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 7.78 \cdot 10^{-8}$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0649.

The average severity of the symptom across all interviews is 1.47 times higher in vaccinated than in the non-vaccinated.



3.6 New symptom: Cough


The occurrence of the symptom “Cough” to the question “Have you experienced a NEW symptom in the last 14 days?”.



4.85% ($n = 5661$) of the non-vaccinated reported that the new symptom Cough had occurred in the last 14 days, compared to 6.37% ($n = 396$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.31 times more often than the control group. The difference in proportions has the significance $p = 1.86 \cdot 10^{-7}$ (Fisher exact test) and an odds ratio of 0.748 (95% confidence interval of 0.673 to 0.834). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.42 in the control group and 2.52 in the vaccinated. Thus, the average severity was 1.04 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0809$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.018.

The average severity of the symptom across all interviews is 1.37 times higher in vaccinated than in the non-vaccinated.



3.7 New symptom: Limb pain


The occurrence of the symptom “Limb pain” to the question “Have you experienced a NEW symptom in the last 14 days?”.



2.53% ($n = 2953$) of the non-vaccinated reported that the new symptom Limb pain had occurred in the last 14 days, compared to 3.75% ($n = 233$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.48 times more often than the control group. The difference in proportions has the significance $p = 2.28 \cdot 10^{-8}$ (Fisher exact test) and an odds ratio of 0.666 (95% confidence interval of 0.581 to 0.766). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.75 in the control group and 2.82 in the vaccinated. Thus, the average severity was 1.03 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.389$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00501.

The average severity of the symptom across all interviews is 1.52 times higher in vaccinated than in the non-vaccinated.



3.8 New symptom: Chills


The occurrence of the symptom “Chills” to the question “Have you experienced a NEW symptom in the last 14 days?”.



1.24% ($n = 1445$) of the non-vaccinated reported that the new symptom Chills had occurred in the last 14 days, compared to 1.69% ($n = 105$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.37 times more often than the control group. The difference in proportions has the significance $p = 0.00285$ (Fisher exact test) and an odds ratio of 0.729 (95% confidence interval of 0.597 to 0.899). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.55 in the control group and 2.31 in the vaccinated. Thus, the average severity was 1.1 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.0235$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0504.

The average severity of the symptom across all interviews is 1.24 times higher in vaccinated than in the non-vaccinated.



3.9 New symptom: Fever


The occurrence of the symptom “Fever” to the question “Have you experienced a NEW symptom in the last 14 days?”.



1.86% ($n = 2177$) of the non-vaccinated reported that the new symptom Fever had occurred in the last 14 days, compared to 2.41% ($n = 150$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.29 times more often than the control group. The difference in proportions has the significance $p = 0.00259$ (Fisher exact test) and an odds ratio of 0.768 (95% confidence interval of 0.649 to 0.914). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.43 in the control group and 2.36 in the vaccinated. Thus, the average severity was 1.03 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.276$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0124.

The average severity of the symptom across all interviews is 1.26 times higher in vaccinated than in the non-vaccinated.



3.10 New symptom: Cardiovascular problems


The occurrence of the symptom “Cardiovascular problems” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.942% ($n = 1101$) of the non-vaccinated reported that the new symptom Cardiovascular problems had occurred in the last 14 days, compared to 2.32% ($n = 144$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.46 times more often than the control group. The difference in proportions has the significance $p = 6.05 \cdot 10^{-20}$ (Fisher exact test) and an odds ratio of 0.401 (95% confidence interval of 0.336 to 0.482). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.41 in the control group and 2.72 in the vaccinated. Thus, the average severity was 1.13 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.00106$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0871.

The average severity of the symptom across all interviews is 2.78 times higher in vaccinated than in the non-vaccinated.



3.11 New symptom: Bruises


The occurrence of the symptom “Bruises” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.205% ($n = 240$) of the non-vaccinated reported that the new symptom Bruises had occurred in the last 14 days, compared to 0.853% ($n = 53$) of the vaccinated. Thus, the vaccinated suffered from this complaint 4.15 times more often than the control group. The difference in proportions has the significance $p = 7.58 \cdot 10^{-16}$ (Fisher exact test) and an odds ratio of 0.239 (95% confidence interval of 0.177 to 0.329). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.14 in the control group and 2.49 in the vaccinated. Thus, the average severity was 1.16 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0451$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.099.

The average severity of the symptom across all interviews is 4.83 times higher in vaccinated than in the non-vaccinated.



3.12 New symptom: Disorder of the lymph systems


The occurrence of the symptom “Disorder of the lymph systems” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.157% ($n = 183$) of the non-vaccinated reported that the new symptom Disorder of the lymph systems had occurred in the last 14 days, compared to 0.354% ($n = 22$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.26 times more often than the control group. The difference in proportions has the significance $p = 0.00105$ (Fisher exact test) and an odds ratio of 0.442 (95% confidence interval of 0.283 to 0.723). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.33 in the control group and 2.86 in the vaccinated. Thus, the average severity was 1.23 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0407$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.122.

The average severity of the symptom across all interviews is 2.77 times higher in vaccinated than in the non-vaccinated.



3.13 New symptom: Dyspnea


The occurrence of the symptom “Dyspnea” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.923% ($n = 1079$) of the non-vaccinated reported that the new symptom Dyspnea had occurred in the last 14 days, compared to 2.09% ($n = 130$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.26 times more often than the control group. The difference in proportions has the significance $p = 1.2 \cdot 10^{-15}$ (Fisher exact test) and an odds ratio of 0.436 (95% confidence interval of 0.363 to 0.529). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.23 in the control group and 2.44 in the vaccinated. Thus, the average severity was 1.09 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0147$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0626.

The average severity of the symptom across all interviews is 2.47 times higher in vaccinated than in the non-vaccinated.



3.14 New symptom: Gastrointestinal problems


The occurrence of the symptom “Gastrointestinal problems” to the question “Have you experienced a NEW symptom in the last 14 days?”.



2.08% ($n = 2425$) of the non-vaccinated reported that the new symptom Gastrointestinal problems had occurred in the last 14 days, compared to 3.09% ($n = 192$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.49 times more often than the control group. The difference in proportions has the significance $p = 3.95 \cdot 10^{-7}$ (Fisher exact test) and an odds ratio of 0.665 (95% confidence interval of 0.573 to 0.776). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.65 in the control group and 2.72 in the vaccinated. Thus, the average severity was 1.03 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.412$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00437.

The average severity of the symptom across all interviews is 1.53 times higher in vaccinated than in the non-vaccinated.



3.15 New symptom: Food intolerance


The occurrence of the symptom “Food intolerance” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.22% ($n = 257$) of the non-vaccinated reported that the new symptom Food intolerance had occurred in the last 14 days, compared to 0.402% ($n = 25$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.83 times more often than the control group. The difference in proportions has the significance $p = 0.00615$ (Fisher exact test) and an odds ratio of 0.546 (95% confidence interval of 0.361 to 0.86). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.81 in the control group and 3 in the vaccinated. Thus, the average severity was 1.07 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.445$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00816.

The average severity of the symptom across all interviews is 1.95 times higher in vaccinated than in the non-vaccinated.



3.16 New symptom: Loss of smell


The occurrence of the symptom “Loss of smell” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.619% ($n = 723$) of the non-vaccinated reported that the new symptom Loss of smell had occurred in the last 14 days, compared to 0.466% ($n = 29$) of the vaccinated. Thus, the non-vaccinated suffered from this complaint 1.33 times more often than the control group. The difference in proportions has the significance $p = 0.155$ (Fisher exact test) and an odds ratio of 1.33 (95% confidence interval of 0.916 to 2).


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.82 in the control group and 2.21 in the vaccinated. Thus, the average severity was 1.28 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.0101$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0846.

The average severity of the symptom across all interviews is 1.70 times higher in non-vaccinated than in the vaccinated.



3.17 New symptom: Chest pains


The occurrence of the symptom “Chest pains” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.46% ($n = 538$) of the non-vaccinated reported that the new symptom Chest pains had occurred in the last 14 days, compared to 1.58% ($n = 98$) of the vaccinated. Thus, the vaccinated suffered from this complaint 3.42 times more often than the control group. The difference in proportions has the significance $p = 1.42 \cdot 10^{-22}$ (Fisher exact test) and an odds ratio of 0.289 (95% confidence interval of 0.232 to 0.363). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.3 in the control group and 2.49 in the vaccinated. Thus, the average severity was 1.08 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.074$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0574.

The average severity of the symptom across all interviews is 3.71 times higher in vaccinated than in the non-vaccinated.



3.18 New symptom: Headache


The occurrence of the symptom “Headache” to the question “Have you experienced a NEW symptom in the last 14 days?”.



3.9% ($n = 4562$) of the non-vaccinated reported that the new symptom Headache had occurred in the last 14 days, compared to 5.9% ($n = 367$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.51 times more often than the control group. The difference in proportions has the significance $p = 1.78 \cdot 10^{-13}$ (Fisher exact test) and an odds ratio of 0.648 (95% confidence interval of 0.58 to 0.725). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.77 in the control group and 2.83 in the vaccinated. Thus, the average severity was 1.02 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.23$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0105.

The average severity of the symptom across all interviews is 1.54 times higher in vaccinated than in the non-vaccinated.



3.19 New symptom: Fatigue


The occurrence of the symptom “Fatigue” to the question “Have you experienced a NEW symptom in the last 14 days?”.



4.45% ($n = 5203$) of the non-vaccinated reported that the new symptom Fatigue had occurred in the last 14 days, compared to 6.84% ($n = 425$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.54 times more often than the control group. The difference in proportions has the significance $p = 1.9 \cdot 10^{-16}$ (Fisher exact test) and an odds ratio of 0.635 (95% confidence interval of 0.573 to 0.705). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.89 in the control group and 3.01 in the vaccinated. Thus, the average severity was 1.04 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0386$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0236.

The average severity of the symptom across all interviews is 1.59 times higher in vaccinated than in the non-vaccinated.



3.20 New symptom: Lack of motivation


The occurrence of the symptom “Lack of motivation” to the question “Have you experienced a NEW symptom in the last 14 days?”.



3.05% ($n = 3567$) of the non-vaccinated reported that the new symptom Lack of motivation had occurred in the last 14 days, compared to 5.03% ($n = 313$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.65 times more often than the control group. The difference in proportions has the significance $p = 5.94 \cdot 10^{-16}$ (Fisher exact test) and an odds ratio of 0.594 (95% confidence interval of 0.527 to 0.671). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.96 in the control group and 2.98 in the vaccinated. Thus, the average severity was 1.01 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.663$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00675.

The average severity of the symptom across all interviews is 1.66 times higher in vaccinated than in the non-vaccinated.



3.21 New symptom: Insomnia


The occurrence of the symptom “Insomnia” to the question “Have you experienced a NEW symptom in the last 14 days?”.



1.73% ($n = 2022$) of the non-vaccinated reported that the new symptom Insomnia had occurred in the last 14 days, compared to 3.47% ($n = 216$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.01 times more often than the control group. The difference in proportions has the significance $p = 2.65 \cdot 10^{-19}$ (Fisher exact test) and an odds ratio of 0.489 (95% confidence interval of 0.424 to 0.567). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.69 in the control group and 2.75 in the vaccinated. Thus, the average severity was 1.02 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.477$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00123.

The average severity of the symptom across all interviews is 2.05 times higher in vaccinated than in the non-vaccinated.



3.22 New symptom: Restlessness


The occurrence of the symptom “Restlessness” to the question “Have you experienced a NEW symptom in the last 14 days?”.



1% ($n = 1169$) of the non-vaccinated reported that the new symptom Restlessness had occurred in the last 14 days, compared to 1.82% ($n = 113$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.82 times more often than the control group. The difference in proportions has the significance $p = 1.81 \cdot 10^{-8}$ (Fisher exact test) and an odds ratio of 0.546 (95% confidence interval of 0.449 to 0.669). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.79 in the control group and 2.75 in the vaccinated. Thus, the average severity was 1.01 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.718$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0161.

The average severity of the symptom across all interviews is 1.79 times higher in vaccinated than in the non-vaccinated.



3.23 New symptom: Tenseness


The occurrence of the symptom “Tenseness” to the question “Have you experienced a NEW symptom in the last 14 days?”.



1.18% ($n = 1380$) of the non-vaccinated reported that the new symptom Tenseness had occurred in the last 14 days, compared to 2.3% ($n = 143$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.95 times more often than the control group. The difference in proportions has the significance $p = 2.15 \cdot 10^{-12}$ (Fisher exact test) and an odds ratio of 0.508 (95% confidence interval of 0.426 to 0.609). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.73 in the control group and 2.64 in the vaccinated. Thus, the average severity was 1.03 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.499$ (Wilcoxon-Mann-Whitney test) and an effect size of $8.81 \cdot 10^{-5}$.

The average severity of the symptom across all interviews is 1.89 times higher in vaccinated than in the non-vaccinated.



3.24 New symptom: Anxiety states


The occurrence of the symptom “Anxiety states” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.808% ($n = 944$) of the non-vaccinated reported that the new symptom Anxiety states had occurred in the last 14 days, compared to 1.22% ($n = 76$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.51 times more often than the control group. The difference in proportions has the significance $p = 0.000912$ (Fisher exact test) and an odds ratio of 0.658 (95% confidence interval of 0.52 to 0.844). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.73 in the control group and 2.83 in the vaccinated. Thus, the average severity was 1.04 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.43$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00555.

The average severity of the symptom across all interviews is 1.57 times higher in vaccinated than in the non-vaccinated.



3.25 New symptom: Double vision (diplopia)


The occurrence of the symptom “Double vision (diplopia)” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.122% ($n = 142$) of the non-vaccinated reported that the new symptom Double vision (diplopia) had occurred in the last 14 days, compared to 0.354% ($n = 22$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.91 times more often than the control group. The difference in proportions has the significance $p = 3 \cdot 10^{-5}$ (Fisher exact test) and an odds ratio of 0.343 (95% confidence interval of 0.218 to 0.565). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.35 in the control group and 2.27 in the vaccinated. Thus, the average severity was 1.03 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.799$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0654.

The average severity of the symptom across all interviews is 2.82 times higher in vaccinated than in the non-vaccinated.



3.26 New symptom: Concentration difficulties


The occurrence of the symptom “Concentration difficulties” to the question “Have you experienced a NEW symptom in the last 14 days?”.



1.08% ($n = 1266$) of the non-vaccinated reported that the new symptom Concentration difficulties had occurred in the last 14 days, compared to 2.46% ($n = 153$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.27 times more often than the control group. The difference in proportions has the significance $p = 3.11 \cdot 10^{-18}$ (Fisher exact test) and an odds ratio of 0.434 (95% confidence interval of 0.366 to 0.518). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.7 in the control group and 2.77 in the vaccinated. Thus, the average severity was 1.03 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.378$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00826.

The average severity of the symptom across all interviews is 2.33 times higher in vaccinated than in the non-vaccinated.



3.27 New symptom: Word finding disorders


The occurrence of the symptom “Word finding disorders” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.555% ($n = 649$) of the non-vaccinated reported that the new symptom Word finding disorders had occurred in the last 14 days, compared to 1.64% ($n = 102$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.95 times more often than the control group. The difference in proportions has the significance $p = 2.38 \cdot 10^{-19}$ (Fisher exact test) and an odds ratio of 0.335 (95% confidence interval of 0.271 to 0.417). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.33 in the control group and 2.31 in the vaccinated. Thus, the average severity was 1.01 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.871$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0413.

The average severity of the symptom across all interviews is 2.93 times higher in vaccinated than in the non-vaccinated.



3.28 New symptom: Coordination difficulties


The occurrence of the symptom “Coordination difficulties” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.211% ($n = 247$) of the non-vaccinated reported that the new symptom Coordination difficulties had occurred in the last 14 days, compared to 0.756% ($n = 47$) of the vaccinated. Thus, the vaccinated suffered from this complaint 3.58 times more often than the control group. The difference in proportions has the significance $p = 3.26 \cdot 10^{-12}$ (Fisher exact test) and an odds ratio of 0.278 (95% confidence interval of 0.203 to 0.389). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.38 in the control group and 2.43 in the vaccinated. Thus, the average severity was 1.02 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.687$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0284.

The average severity of the symptom across all interviews is 3.65 times higher in vaccinated than in the non-vaccinated.



3.29 New symptom: Neurological disorders


The occurrence of the symptom “Neurological disorders” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.179% ($n = 209$) of the non-vaccinated reported that the new symptom Neurological disorders had occurred in the last 14 days, compared to 0.547% ($n = 34$) of the vaccinated. Thus, the vaccinated suffered from this complaint 3.06 times more often than the control group. The difference in proportions has the significance $p = 8.85 \cdot 10^{-8}$ (Fisher exact test) and an odds ratio of 0.326 (95% confidence interval of 0.226 to 0.484). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.71 in the control group and 2.59 in the vaccinated. Thus, the average severity was 1.05 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.717$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0367.

The average severity of the symptom across all interviews is 2.92 times higher in vaccinated than in the non-vaccinated.



3.30 New symptom: Paresthesia on the skin


The occurrence of the symptom “Paresthesia on the skin” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.424% ($n = 495$) of the non-vaccinated reported that the new symptom Paresthesia on the skin had occurred in the last 14 days, compared to 0.901% ($n = 56$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.13 times more often than the control group. The difference in proportions has the significance $p = 1.16 \cdot 10^{-6}$ (Fisher exact test) and an odds ratio of 0.468 (95% confidence interval of 0.354 to 0.629). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.65 in the control group and 3.05 in the vaccinated. Thus, the average severity was 1.15 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.015$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0925.

The average severity of the symptom across all interviews is 2.45 times higher in vaccinated than in the non-vaccinated.



3.31 New symptom: Ekzema, Dermatitis


The occurrence of the symptom “Ekzema, Dermatitis” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.458% ($n = 535$) of the non-vaccinated reported that the new symptom Ekzema, Dermatitis had occurred in the last 14 days, compared to 1.16% ($n = 72$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.53 times more often than the control group. The difference in proportions has the significance $p = 3.94 \cdot 10^{-11}$ (Fisher exact test) and an odds ratio of 0.393 (95% confidence interval of 0.306 to 0.51). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.57 in the control group and 2.65 in the vaccinated. Thus, the average severity was 1.03 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.514$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.00139.

The average severity of the symptom across all interviews is 2.61 times higher in vaccinated than in the non-vaccinated.



3.32 New symptom: Allergies


The occurrence of the symptom “Allergies” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.353% ($n = 412$) of the non-vaccinated reported that the new symptom Allergies had occurred in the last 14 days, compared to 0.788% ($n = 49$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.24 times more often than the control group. The difference in proportions has the significance $p = 1.12 \cdot 10^{-6}$ (Fisher exact test) and an odds ratio of 0.445 (95% confidence interval of 0.33 to 0.613). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.59 in the control group and 3 in the vaccinated. Thus, the average severity was 1.16 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0291$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0882.

The average severity of the symptom across all interviews is 2.58 times higher in vaccinated than in the non-vaccinated.



3.33 New symptom: Herpes zoster


The occurrence of the symptom “Herpes zoster” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.284% ($n = 332$) of the non-vaccinated reported that the new symptom Herpes zoster had occurred in the last 14 days, compared to 0.418% ($n = 26$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.47 times more often than the control group. The difference in proportions has the significance $p = 0.0682$ (Fisher exact test) and an odds ratio of 0.679 (95% confidence interval of 0.454 to 1.06).


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.5 in the control group and 2.73 in the vaccinated. Thus, the average severity was 1.09 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.288$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0296.

The average severity of the symptom across all interviews is 1.61 times higher in vaccinated than in the non-vaccinated.



3.34 New symptom: Joint inflammation


The occurrence of the symptom “Joint inflammation” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.395% ($n = 461$) of the non-vaccinated reported that the new symptom Joint inflammation had occurred in the last 14 days, compared to 1.24% ($n = 77$) of the vaccinated. Thus, the vaccinated suffered from this complaint 3.14 times more often than the control group. The difference in proportions has the significance $p = 3.06 \cdot 10^{-16}$ (Fisher exact test) and an odds ratio of 0.316 (95% confidence interval of 0.247 to 0.408). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.65 in the control group and 2.91 in the vaccinated. Thus, the average severity was 1.1 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.0591$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0674.

The average severity of the symptom across all interviews is 3.44 times higher in vaccinated than in the non-vaccinated.



3.35 New symptom: Overdue menses


The occurrence of the symptom “Overdue menses” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.0847% ($n = 99$) of the non-vaccinated reported that the new symptom Overdue menses had occurred in the last 14 days, compared to 0.499% ($n = 31$) of the vaccinated. Thus, the vaccinated suffered from this complaint 5.88 times more often than the control group. The difference in proportions has the significance $p = 3.63 \cdot 10^{-13}$ (Fisher exact test) and an odds ratio of 0.169 (95% confidence interval of 0.112 to 0.262). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 3.35 in the control group and 3.1 in the vaccinated. Thus, the average severity was 1.08 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.442$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0128.

The average severity of the symptom across all interviews is 5.43 times higher in vaccinated than in the non-vaccinated.



3.36 New symptom: Increased menstrual problems


The occurrence of the symptom “Increased menstrual problems” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.206% ($n = 241$) of the non-vaccinated reported that the new symptom Increased menstrual problems had occurred in the last 14 days, compared to 0.354% ($n = 22$) of the vaccinated. Thus, the vaccinated suffered from this complaint 1.72 times more often than the control group. The difference in proportions has the significance $p = 0.0226$ (Fisher exact test) and an odds ratio of 0.582 (95% confidence interval of 0.375 to 0.947). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 3.24 in the control group and 2.77 in the vaccinated. Thus, the average severity was 1.17 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.0729$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0897.

The average severity of the symptom across all interviews is 1.47 times higher in vaccinated than in the non-vaccinated.



3.37 New symptom: General overall symptoms (e.g. migraine) improved


The occurrence of the symptom “General overall symptoms (e.g. migraine) improved” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.11% ($n = 129$) of the non-vaccinated reported that the new symptom General overall symptoms (e.g. migraine) improved had occurred in the last 14 days, compared to 0.225% ($n = 14$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.04 times more often than the control group. The difference in proportions has the significance $p = 0.019$ (Fisher exact test) and an odds ratio of 0.49 (95% confidence interval of 0.281 to 0.921). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.51 in the control group and 2.36 in the vaccinated. Thus, the average severity was 1.07 times greater in the non-vaccinated than in the vaccinated. The difference in the averages has the significance $p = 0.688$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0411.

The average severity of the symptom across all interviews is 1.91 times higher in vaccinated than in the non-vaccinated.



3.38 New symptom: Increased general overall symptoms


The occurrence of the symptom “Increased general overall symptoms” to the question “Have you experienced a NEW symptom in the last 14 days?”.



0.352% ($n = 411$) of the non-vaccinated reported that the new symptom Increased general overall symptoms had occurred in the last 14 days, compared to 0.82% ($n = 51$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.33 times more often than the control group. The difference in proportions has the significance $p = 3.01 \cdot 10^{-7}$ (Fisher exact test) and an odds ratio of 0.427 (95% confidence interval of 0.318 to 0.583). The confidence interval does not contain the one and supports the significance statement.


Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.94 in the control group and 2.96 in the vaccinated. Thus, the average severity was 1.01 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.945$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0742.

The average severity of the symptom across all interviews is 2.35 times higher in vaccinated than in the non-vaccinated.



3.39 New symptom: Remarkable weight gain


The occurrence of the symptom “Remarkable weight gain” to the question “Have you experienced a NEW symptom in the last 14 days?”.




0.147% ($n = 172$) of the non-vaccinated reported that the new symptom Remarkable weight gain had occurred in the last 14 days, compared to 0.386% ($n = 24$) of the vaccinated. Thus, the vaccinated suffered from this complaint 2.62 times more often than the control group. The difference in proportions has the significance $p = 9.86 \cdot 10^{-5}$ (Fisher exact test) and an odds ratio of 0.38 (95% confidence interval of 0.247 to 0.61). The confidence interval does not contain the one and supports the significance statement.

Within those suffering from these symptoms in both cohorts, the average severity of suffering is 2.35 in the control group and 2.71 in the vaccinated. Thus, the average severity was 1.15 times greater in the vaccinated than in the control group. The difference in the averages has the significance $p = 0.104$ (Wilcoxon-Mann-Whitney test) and an effect size of 0.0901.

The average severity of the symptom across all interviews is 3.02 times higher in vaccinated than in the non-vaccinated.



3.40 Occurrence of symptomatic SARS-CoV2 infection



The response to the question 'Have you had a symptomatic SARS-CoV2 infection in the last 14 days' is presented. The response is split by Covid vaccination status. For people who were vaccinated during the interviews, interviews before vaccination are assigned to the control group, and interviews after vaccination are assigned to the vaccinated group.

